German CRO subsidiary specializing in rare disease clinical trial management, with experience in retinal degeneration and cystic fibrosis pivotal trials.
Smerud Medical Research Germany GmbH is the German subsidiary of Smerud Medical Research, a Contract Research Organization (CRO) specializing in clinical trial management and regulatory strategy for rare and orphan diseases. They are brought into research consortia as third-party service providers — contributing clinical development expertise including trial design, GCP-compliant execution, and regulatory pathway planning — rather than as independent research actors. In H2020, they supported two distinct rare disease programs: a regenerative therapy targeting retinal degeneration (Stargardt's disease) and a pivotal Phase IIb inhaled compound trial for cystic fibrosis. Their core value to consortia is translating academic research assets into clinically executable, regulator-ready development plans.
Participated as third-party clinical expert in both Soraprazan (Stargardt's disease) and OligoGpivotalCF (cystic fibrosis), covering distinct therapeutic modalities across two programs.
Contributed to Soraprazan, a regenerative therapy program targeting lipofuscin accumulation and RPE cell degeneration in Stargardt's disease.
Supported OligoGpivotalCF, a Phase IIb pivotal trial of inhaled alginate oligosaccharide as a mutation-independent therapy for cystic fibrosis.
Both engagements involved clinical development and pivotal trial frameworks, consistent with regulatory strategy support typical of CRO third-party roles.
Their two H2020 engagements show a shift from early-stage regenerative ophthalmology (Stargardt's disease, RPE cell biology, lipofuscin — 2017) toward later-stage, registration-track respiratory trials (pivotal Phase IIb, clinical development, mutation-independent therapy — 2018). This is not a change in core competence but a progression: from supporting a proof-of-concept rare disease program to contributing to a pivotal trial closer to regulatory submission. The trajectory suggests increasing involvement in advanced-phase clinical execution rather than early exploratory research.
They appear to be moving toward later-stage, pivotal-trial engagements in rare diseases — making them most relevant to consortia that have passed proof-of-concept and need CRO expertise for Phase IIb/III execution.
Smerud Medical Research Germany operates exclusively as a third party — a subcontracted specialist embedded in consortia rather than a co-investigator or leader. This means they are engaged for specific clinical expertise on a contracted basis, which suits academic or biotech-led consortia that lack in-house CRO capabilities. With 15 unique partners across 6 countries from only 2 projects, they clearly operate within large, international, multi-partner programs typical of H2020 health trials.
Despite only two H2020 projects, they connected with 15 distinct consortium partners across 6 countries — reflecting the large, multi-site trial networks typical of rare disease clinical programs. Their network is pan-European rather than Germany-centric.
As a CRO subsidiary embedded in EU research consortia, Smerud Germany occupies a niche that pure academic or industrial partners cannot easily fill: they bring GCP-compliant clinical trial infrastructure and rare disease regulatory knowledge to academic-led projects that would otherwise lack a clinical execution arm. Their experience spanning both ophthalmological and pulmonary rare diseases makes them unusually cross-indication versatile for a company of this size. For a consortium planning a Phase II or pivotal trial in orphan disease, they represent a ready-made clinical operations partner without the overhead of a large CRO.
